Identification of novel osteogenic compounds by an ex-vivo sp7: Luciferase zebrafish scale assay

Bone

Volumn 74, Issue , 2015, Pages 106-113

  de Vrieze, Erik ^a   Zethof, Jan ^a   Schulte Merker, Stefan ^b,c,d   Flik, Gert ^a   Metz, Juriaan R ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c INST OF REPRO MED OF THE UNIV   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Bone; Drug design; Elasmoid scales; Osteoblast; Sp7; Zebrafish

Indexed keywords

1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; 2 CHLORO 5 NITROBENZANILIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 5 AZA 2' DEOXYCYTIDINE; 7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; APIGENIN; BML 285; CARNOSOL; CELECOXIB; CURCUMIN; DICLOFENAC; DOXORUBICIN; ELLAGIC ACID; EXIFONE; GENISTEIN; IMATINIB; NICLOSAMIDE; PROSTAGLANDIN E2; PYRVINIUM EMBONATE; RECOMBINANT BONE MORPHOGENETIC PROTEIN; RESVERATROL; RETINOIC ACID; RILUZOLE; ROSIGLITAZONE; SULINDAC; SULINDAC SULFIDE; THALIDOMIDE; TRANSCRIPTION FACTOR OSTERIX; UNCLASSIFIED DRUG; UNINDEXED DRUG; USNIC ACID; BONE MORPHOGENETIC PROTEIN 2; LUCIFERASE; OSTERIX PROTEIN, ZEBRAFISH; TRANSCRIPTION FACTOR; WNT PROTEIN; ZEBRAFISH PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL STRUCTURES; ANIMAL TISSUE; ARTICLE; BONE DEVELOPMENT; CELL ACTIVITY; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; ENZYME ACTIVITY; EX VIVO STUDY; EXPLANT; FISH SCALE; LUCIFERASE ASSAY; LUCIFERASE ZEBRAFISH SCALE ASSAY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TISSUE REGENERATION; TRANSGENIC ZEBRAFISH; WNT SIGNALING PATHWAY; ANIMAL; BIOASSAY; GENETICS; METABOLISM; PROCEDURES; PROMOTER REGION; REGENERATION; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL; ZEBRA FISH;

ANIMAL STRUCTURES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BIOLOGICAL ASSAY; BONE MORPHOGENETIC PROTEIN 2; LUCIFERASES; OSTEOBLASTS; OSTEOGENESIS; PROMOTER REGIONS, GENETIC; REGENERATION; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; WNT PROTEINS; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84921716985     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2015.01.006     Document Type: Article

References (56)

1. Auld D.S., Farmen M.W., Kahl S.D., Kriauciunas A., McKnight K.L., Montrose C., et al. Receptor binding assays for HTS and drug discovery. Assay Guidance, Manual 2004, Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda (MD). G.S. Sittampalam, N. Gal-Edd, M. Arkin, D.S. Auld, C. Austin, B. Bejcek (Eds.).
2. Roth J., Minond D., Darout E., Liu Q., Lauer J., Hodder P., et al. Identification of novel, exosite-binding matrix metalloproteinase-13 inhibitor scaffolds. Bioorg Med Chem Lett 2011, 21:7180-7184.
3. Calamini B., Silva M.C., Madoux F., Hutt D.M., Khanna S., Chalfant M.A., et al. Small-molecule proteostasis regulators for protein conformational diseases. Nat Chem Biol 2012, 8:185-196.
4. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J Health Econ 2003, 22:151-185.
5. Kaitin K.I. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther 2010, 87:356-361.
6. Rissanen J.P., Halleen J.M. Models and screening assays for drug discovery in osteoporosis. Expert Opin Drug Discov 2010, 5:1163-1174.
7. Eriksen E.F. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 2010, 11:219-227.
8. Uusitalo H., Rantakokko J., Ahonen M., Jamsa T., Tuukkanen J., KaHari V., et al. A metaphyseal defect model of the femur for studies of murine bone healing. Bone 2001, 28:423-429.
9. Lelovas P.P., Xanthos T.T., Benzing T., Lyritis G.P., Dontasi I.A. The laboratory rat as an animal model for osteoporosis research. Comp Med 2008, 58:424-430.
10. Wu X., Downes S., Watts D.C. Evaluation of critical size defects of mouse calvarial bone: an organ culture study. Microsc Res Tech 2010, 73:540-547.
11. Renn J., Winkler C., Schartl M., Fischer R., Goerlich R. Zebrafish and medaka as models for bone research including implications regarding space-related issues. Protoplasma 2006, 229:209-214.
12. Apschner A., Huitema L.F.A., Ponsioen B., Peterson-Maduro J., Schulte-Merker S. Pathological mineralization in a zebrafish enpp1 mutant exhibits features of Generalized Arterial Calcification of Infancy (GACI) and Pseudoxanthoma Elasticum (PXE). Dis Model Mech 2014, 7(7):811-822.
13. Mitchell R.E., Huitema L.F.A., Skinner R.E.H., Brunt L.H., Severn C., Schulte-Merker S., et al. New tools for studying osteoarthritis genetics in zebrafish. Osteoarthr Cartil 2013, 21:269-278.
14. To T.T., Witten P.E., Renn J., Bhattacharya D., Huysseune A., Winkler C. Rankl-induced osteoclastogenesis leads to loss of mineralization in a medaka osteoporosis model. Development 2012, 139:141-150.
15. Witten P.E., Hansen A., Hall B.K. Features of mono- and multinucleated bone resorbing cells of the zebrafish (Danio rerio) and their contribution to skeletal development, remodeling, and growth. J Morphol 2001, 250:197-207.
16. Fleming A., Sato M., Goldsmith P. High-throughput in vivo screening for bone anabolic compounds with zebrafish. J Biomol Screen 2005, 10:823-831.
17. Metz J.R., de Vrieze E., Lock E.J., Schulten I.E., Flik G. Elasmoid scales of fishes as model in biomedical bone research. J Appl Ichthyol 2012, 28:382-387.
18. de Vrieze E., Moren M., Metz J.R., Flik G., Lie K.K. Arachidonic acid enhances turnover of the dermal skeleton: studies on zebrafish scales. PLoS One 2014, 9:e89347.
19. de Vrieze E., van Kessel M.A.H.J., Peters H.M., Spanings F.A.T., Flik G., Metz J.R. Prednisolone induces osteoporosis-like phenotype in regenerating zebrafish scales. Osteoporos Int 2014, 25(2):567-578.
20. Metz J.R., Leeuwis R., Zethof J., Flik G. Zebrafish (Danio rerio) in calcium-poor water mobilise calcium and phosphorus from scales. J Appl Ichthyol 2014, 671-677.
21. 2+ flux rates and internal calcium pools in the freshwater cichlid teleost, Oreochromis mossambicus. J Exp Biol 1986, 120:249-264.
22. Persson P., Sundell K., Björnsson B.T. Estradiol-17β-induced calcium uptake and resorption in juvenile rainbow trout, Oncorhynchus mykiss. Fish Physiol Biochem 1994, 379-386.
23. Redruello B., Estevao M.D., Rotllant J., Guerreiro P.M., Anjos L.I., Canario A.V., et al. Isolation and characterization of piscine osteonectin and downregulation of its expression by PTH-related protein. J Bone Miner Res 2005, 20:682-692.
24. Rotllant J., Redruello B., Guerreiro P.M., Fernandes H., Canario A.V., Power D.M. Calcium mobilization from fish scales is mediated by parathyroid hormone related protein via the parathyroid hormone type 1 receptor. Regul Pept 2005, 132:33-40.
25. Yoshikubo H., Suzuki N., Takemura K., Hoso M., Yashima S., Iwamuro S., et al. Osteoblastic activity and estrogenic response in the regenerating scale of goldfish, a good model of osteogenesis. Life Sci 2005, 76:2699-2709.
26. Suzuki N., Danks J.A., Maruyama Y., Ikegame M., Sasayama Y., Hattori A., et al. Parathyroid hormone 1 (1-34) acts on the scales and involves calcium metabolism in goldfish. Bone 2011, 48:1186-1193.
27. Nakashima K., Zhou X., Kunkel G., Zhang Z., Deng J.M., Behringer R.R., et al. The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell 2002, 108:17-29.
28. Matsubara T., Kida K., Yamaguchi A., Hata K., Ichida F., Meguro H., et al. BMP2 regulates osterix through Msx2 and Runx2 during osteoblast differentiation. J Biol Chem 2008, 283:29119-29125.
29. Baron R., Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab 2012, 97:311-325.
30. Westerfield M. The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio) 2010, University of Oregon Press, Eugene. 4th ed.
31. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002, 3. [research0034.1-research0034.11].
32. Spoorendonk K.M., Peterson-Maduro J., Renn J., Trowe T., Kranenbarg S., Winkler C., et al. Retinoic acid and Cyp26b1 are critical regulators of osteogenesis in the axial skeleton. Development 2008, 135:3765-3774.
33. Renn J., Winkler C. Osterix-mCherry transgenic medaka for in vivo imaging of bone formation. Dev Dyn 2009, 238:241-248.
34. Suster M.L., Kikuta H., Urasaki A., Asakawa K., Kawakami K. Transgenesis in zebrafish with the Tol2 transposon system. Transgenesis techniques 2009, 41-63.
35. Pombinho A.R., Laize V., Molha D.M., Marques S.M., Cancela M.L. Development of two bone-derived cell lines from the marine teleost Sparus aurata; evidence for extracellular matrix mineralization and cell-type-specific expression of matrix Gla protein and osteocalcin. Cell Tissue Res 2004, 315:393-406.
36. Ignovski J.M., Schaffer D.V. Kinetic analysis and modeling of firefly luciferase as a quantitative reporter gene in live mammalian cells. Biotechnol Bioeng 2004, 86:827-834.
37. Lang T.A., Secic M. How to report statistics in medicine 2006, ACP Press, Philadelphia, PA. 2nd ed.
38. Koumans J.T.M., Sire J.Y. An in vitro, serum-free organ culture technique for the study of development and growth of the dermal skeleton in fish. In Vitro Cell Dev Biol Anim 1996, 32:612-626.
39. Suzuki N., Suzuki T., Kurokawa T. Suppression of osteoclastic activities by calcitonin in the scales of goldfish (freshwater teleost) and nibbler fish (seawater teleost). Peptides 2000, 21:115-124.
40. Pasqualetti S., Banfi G., Mariotti M. The zebrafish scale as model to study the bone mineralization process. J Mol Histol 2012, 43:589-595.
41. de Vrieze E., Metz J.R., den Hoff Von J.W., Flik G. ALP, TRAcP and cathepsin K in elasmoid scales: a role in mineral metabolism?. J Appl Ichthyol 2010, 26:210-213.
42. Rawadi G., Vayssiere B., Dunn F., Baron R., Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003, 18:1842-1853.
43. Enders G.H. Wnt therapy for bone loss: golden goose or Trojan horse?. J Clin Invest 2009, 119:758-760.
44. McClung M.R., Grauer A., Boonen S., Bolognese M.A., Brown J.P., Diez-Perez A., et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 2014, 370:412-420.
45. Dijke ten P., Krause C., de Gorter D.J.J., Lowik C.W.G.M., van Bezooijen R.L. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg 2008, 90:31-35.
46. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139:4252-4263.
47. Yamaguchi M., Weitzmann M.N. The estrogen 17beta-estradiol and phytoestrogen genistein mediate differential effects on osteoblastic NF-kappaB activity. Int J Mol Med 2009, 23:297-301.
48. Banu J., Varela E., Fernandes G. Alternative therapies for the prevention and treatment of osteoporosis. Nutr Rev 2012, 70:22-40.
49. Bellingham M.C. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade?. CNS Neurosci Ther 2011, 17:4-31.
50. Chenu C., Serre C.M., Raynal C., Burt-Pichat B., Delmas P.D. Glutamate receptors are expressed by bone cells and are involved in bone resorption. Bone 1998, 22:295-299.
51. Genever P.G., Skerry T.M. Regulation of spontaneous glutamate release activity in osteoblastic cells and its role in differentiation and survival: evidence for intrinsic glutamatergic signaling in bone. FASEB J 2001, 15:1586.
52. Brakspear K.S., Mason D.J. Glutamate signaling in bone. Front Endocrinol 2012, 3:97.
53. Chellaiah M.A., Schaller M.D. Activation of Src kinase by protein-tyrosine phosphatase-PEST in osteoclasts: comparative analysis of the effects of bisphosphonate and protein-tyrosine phosphatase inhibitor on Src activation in vitro. J Cell Physiol 2009, 220:382-393.
54. Lee C.-H., Huang Y.-L., Liao J.-F., Chiou W.-F. Ugonin K-stimulated osteogenesis involves estrogen receptor-dependent activation of non-classical Src signaling pathway and classical pathway. Eur J Pharmacol 2012, 676:26-33.
55. Chen M., Wang J., Lu J., Bond M.C., Ren X.-R., Lyerly H.K., et al. The anti-helminthic niclosamide inhibits Wnt/Frizzled1 signaling. Biochemistry 2009, 48:10267-10274.
56. Hatta M., Yoshimura Y., Deyama Y., Fukamizu A., Suzuki K. Molecular characterization of the zinc finger transcription factor, osterix. Int J Mol Med 2006, 17:425-430.